Key result
Spironolactone 25 mg/day did not significantly affect serum potassium levels compared to placebo in CAPD patients with a history of hypokalemia (3.90 vs 3.91 mEq/L after 4 weeks).
Why the study?
Does oral spironolactone 25 mg/day improve serum potassium in continuous ambulatory peritoneal dialysis patients with a history of hypokalemia?
Population
24 continuous ambulatory peritoneal dialysis (CAPD) patients with a history of hypokalemia (10 anuric)
Comparison
Oral spironolactone 25 mg/day for 4 weeks vs Placebo for 4 weeks
Design
RCT, Randomized cross-over, Double-blind
Follow-up
4 weeks per treatment period
Authors
Loading...
Does not support spironolactone for hypokalemia correction in CAPD; confirms neutral potassium effect and directs research to alternatives.
RCT (n=24)
double-blind
randomized
Does oral spironolactone 25 mg/day improve serum potassium in continuous ambulatory peritoneal dialysis patients with a history of hypokalemia?
Absolute Event Rate: 3.9% vs 3.91%
Spironolactone 25 mg/day does not significantly affect serum potassium or excretion rates in CAPD patients with a history of hypokalemia.
Yongsiri et al. (2014) conducted an RCT in Hypokalemia in continuous ambulatory peritoneal dialysis (CAPD) (n=24). Spironolactone vs. Placebo was evaluated on difference of serum potassium before and after 4 weeks of treatment. Spironolactone 25 mg/day did not significantly affect serum potassium levels compared to placebo in CAPD patients with a history of hypokalemia (3.90 vs 3.91 mEq/L after 4 weeks).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: